Rob Wilechansky

Transplant Hepatologist @OHSUGastro. Formerly @MGH_GI, @BMCimRES, and AASLD ELS. Grad of @ColumbiaPS and @WilliamsCollege. #Milanista 🔴⚫️

[Hepatology Communications @HepCommJournal]

📑 A natural language processing algorithm accurately classifies steatotic liver disease pathology to estimate the risk of #cirrhosis❕
#NLP #LiverTwitter #LiverX

[Alan Bonder @BonderAlan]

Big news in the world of liver disease! The FDA has approved Elafibranor for patients with PBC. This is a huge step forward in the treatment of this chronic condition and offers new hope to those affected. #PBC #Elafibranor #FDAapproval

[Mazen Noureddin, MD, MHSc @NoureddinMD]

Hot off the press: Survodutide efficacy in#MASH including both MASH resolution & fibrosis improvement presented ⁦@EASLedu⁩ and published ⁦@NEJM⁩ today! ⁦@ArunJSanyalVCU⁩ ⁦@AlkhouriNaim⁩ ⁦@RamyYounes9⁩ #livertwitter

[Kavish Patidar @KavishPatidar11]

Targeting MAP is crucial to hasten AKI recovery. See➡️ https://t.co/kVzX6A2GF6 by the mad genius @JoeCullaro

Need more evidence?
➡️ https://t.co/e0CtbNQ5IK
➡️ https://t.co/MhiZDHxL0l

@AASLDtweets @ICA_Global_AKI @HrsHarmony

[Nneka N. Ufere, MD MSCE @NnekaUfereMD]

Big month for #MASLD trials - as we discuss costs of medications, nice to see the potential of low-cost alternatives. Congratulations to my favorite @traceyg_md (proud of you friend) and @WilechanskyMD @KathleenCoreyMD @DrLoomba @raychungmd @AndyChanMD @MGH_GI #livertwitter #mash

[HEPATOLOGY Journal @HEP_Journal]

Did you know about our new Fellows' Corner?
Keeping up with an ever-evolving literature during GI and hepatology training is not an easy task.
Here @WilechanskyMD discuss 3 papers with meaningful developments for diagnostics and therapeutics in hepatology!
https://t.co/eN3IXhRuiI

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

Our DECEMBER ISSUE is live! Alcohol-related liver disease and MASLD, HCC surveillance, intestinal hormones, IBD, and much more!
https://t.co/NbdzVS3w0C

[Liver Transplantation Journal (LTxJournal) @LTxJournal]

Great to see the @LTxJournal & @HEP_Journal editorial fellows together at #TLM23 - @AlanLHutchison & @WilechanskyMD! 🔥

#livertwitter

[George Ioannou @gnioannou]

While waiting for prohibitively expensive meds to be FDA approved for MASLD/MASH…
this high-quality *RCT* demonstrated that 6 months of ASPIRIN reduced
- Liver Fat❗️
- liver stiffness, liver enzymes, cT1❗️❗️

By:
@traceyg_md @WilechanskyMD @KathleenCoreyMD @raychungmd

[Liver Talks: The Liver Fellow Network Podcast @Liver_Talks]

New episode! New host! We're ecstatic to welcome our new fellow lead #PatrickLee from @USC_KeckGILiver. Discussion is centered around finding a job, negotiation etc. We welcome back @WilechanskyMD to discuss what's new in @HEP_Journal. @LiverFellow @AASLDtweets

[Arun J. Sanyal @ArunJSanyalVCU]

🆕REVIEW: Digital pathology and artificial intelligence in non-alcoholic steatohepatitis
➡️Current status and future directions. Read it here👉 https://t.co/69QDAgJz6J via @JHepatology #LiverTwitter

[HEPATOLOGY Journal @HEP_Journal]

🚨 @AASLDtweets Practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis 🚨 JUST RELEASED
https://t.co/52y1BQo0km
#LiverTwitter #LiverX

[Liver Talks: The Liver Fellow Network Podcast @Liver_Talks]

Hi! We were fortunate to spend time with @docamitgs to talk about the latest @AASLD HCC guidelines.

In a new segment, we have @HEP_Journal editorial fellow @WilechanskyMD on to discuss outcomes from NASH clinical trial. @LiverFellow @UTSWNews

🍏: https://t.co/yhkoStAnqZ

[Rob Wilechansky @WilechanskyMD]

@AASLDFoundation Grateful to the Foundation and the wonderful family of Dr. Sundaram for this honor, and a special thanks to my mentors for their incredible support (@traceyg_md @raychungmd @AndyChanMD @MGH_GI)!!

[Tony Breu @tony_breu]

1/15
🤔Why does portal hypertension lead to splenomegaly.

I also assumed the spleen became "congested" from backflow of blood.

Turns out, it isn't that simple. And there are interesting therapeutic implications.

Let's have a look.

[HEPATOLOGY Journal @HEP_Journal]

REVIEW‼️
Friedman S & Sanyal A.
The future of hepatology:
✅Basic and translational science
✅Data management
✅Artificial intelligence
✅Precision medicine
https://t.co/KfWfrOvtmJ

[HEPATOLOGY Journal @HEP_Journal]

#HEP_highlight Saving Livers, One Blocker at a Time: A Bayesian Twist on CLD Management
✅Beta-blocker treatment is associated with a high probability of clinical benefit
#LiverTwitter
https://t.co/hwfMqbzMTK

[HEPATOLOGY Journal @HEP_Journal]

#HEP_highlights Before the biopsy: Accuracy of NITs in NAFLD patients with T2DM
Pennisi G et al. LSM and AGILE 3+ individually or in sequential combination after FIB-4 or NFS have a similar good diagnostic accuracy for advanced fibrosis
#LiverTwitter
https://t.co/4WVYE094Kw

[Juan Pablo (JP) Arab, MD  @juanpabloarab]

A global action agenda for turning the tide on fatty liver disease in @HEP_Journal
🚨To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.
#LiverTwitter
https://t.co/DZheiC86aQ

[AASLD Foundation @AASLDFoundation]

Congratulations to our 2023 AASLD Foundation Award Recipients! 🎉Award recipients were selected from a highly competitive applicant pool, demonstrate an exceptional aptitude, and have a deep interest in #liver disease research and treatment. Read more at https://t.co/SfBmF4x3nM.